PineBridge Investments’s Sarepta Therapeutics SRPT Stock Holding History

PineBridge Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,524	Closed	-$608K	–	728
2025 Q1	$608K	Sell	9,524 -15,619	-62%	-$1.64M	﹤0.01%	645
2024 Q4	$3.06M	Buy	25,143 +7,520	+43%	+$922K	0.02%	423
2024 Q3	$2.2M	Buy	+17,623	New	+$2.44M	0.02%	453

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

PineBridge Investments's SRPT Position: Q2 2025 in Review

PineBridge Investments sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 9,524 shares — an estimated $608K sold.

PineBridge Investments first reported a position in SRPT in Q3 2024 and held it in 3 quarters. The position peaked at $3.06M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

PineBridge Investments reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
PineBridge Investments sold 9,524 Sarepta Therapeutics shares in Q2 2025, an estimated $608K.
PineBridge Investments first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 3 quarters.
PineBridge Investments's Sarepta Therapeutics position peaked at $3.06M in Q4 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on PineBridge Investments's 13F filing for Q2 2025, filed 13 Aug 2025.